

1 **Epigenetic Age among U.S. Adults with Chronic Respiratory Diseases: Results**
2 **from NHANES 1999-2002.**

3 ***Research letter***

4 ***Running head: Epigenetic aging in chronic respiratory diseases***

5 Javier Perez-Garcia, PhD^{1,*}, Dennis Khodasevich, PhD¹, Sara De Matteis, MD, MPH,
6 PhD², Mary B. Rice, MD, MPH^{3,4}, Belinda L Needham, PhD⁵, David H Rehkopf, ScD^{1,6,7,8,9},
7 Andres Cardenas, MPH, PhD¹

8 *¹Department of Epidemiology and Population Health, Stanford School of Medicine, Stanford*
9 *University, Stanford, CA, USA.*

10 *²Department of Health Sciences, University of Milan Italy.*

11 *³Division of Pulmonary and Critical Care Medicine, Department of Medicine, Beth Israel*
12 *Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.*

13 *⁴Center for Climate, Health and the Global Environment, Department of Environmental Health,*
14 *Harvard TH Chan School of Public Health*

15 *⁵Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA.*

16 *⁶Department of Medicine (Division of Primary Care and Population Health), Stanford School of*
17 *Medicine, Stanford University, Stanford, CA, USA.*

18 *⁷Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA.*

19 *⁸Department of Health Policy, Stanford School of Medicine, Stanford University, Stanford, CA,*
20 *USA.*

21 *⁹Department of Sociology, Stanford University, Stanford, CA, USA.*

22 **Corresponding author: Javier Perez-Garcia, PhD. Department of Epidemiology and Population*
23 *Health, Stanford University, Stanford, CA, USA. Email: jpegarci@stanford.edu*

24 **Subject category:** CELL AND MOLECULAR BIOLOGY. 3.5 Epigenetics.

25 **Word count (main text; max. 1,000):** 1,067 words.

26 **Number of figures and tables (max. of two display elements):** 1 Figure and 1 Table

27 **Number of references (max. 10):** 10

28 **ABSTRACT**

29 **Background:** Chronic airway diseases are leading causes of mortality and morbidity
30 worldwide. More evidence supports that lung aging can be reflected by changes in DNA
31 methylation, which are relevant for lung diseases, given their ability to capture exposures
32 over a lifetime.

33 **Objective:** We aimed to investigate the association and sex-specific associations of
34 epigenetic age acceleration in whole blood with chronic respiratory diseases.

35 **Methods:** We analyzed public data from 2,402 adults from the National Health and
36 Nutrition Examination Surveys (NHANES) 1999-2002 cycles. We examined the
37 association between epigenetic age and respiratory traits using linear regression models
38 corrected for age, age², gender, race-ethnicity, survey cycles, and survey weights. Multiple
39 comparisons were corrected using a false discovery rate <5%. We conducted stratified
40 analyses by sex and sensitivity analyses adjusted by blood cell counts and clinical and
41 socioeconomic status (SES) confounders.

42 **Results:** Individuals with wheezing showed accelerated epigenetic aging of up to 3.1
43 years (95% Confidence Interval [CI], 2.1, 4.1, $p=8.4 \times 10^{-6}$). Participants with COPD
44 exhibited an epigenetic age acceleration potentially mediated by smoking, while those
45 with emphysema showed epigenetic aging of up to 4.4 years (95% CI: 3.1, 5.8, $p=3.4 \times 10^{-6}$)
46 independent of SES factors. Participants with early-onset COPD and those who ever
47 have asthma showed suggestive accelerated biological aging ($p<0.05$). The accelerated
48 pace of biological aging in COPD participants and the telomere length reduction in
49 wheezing subjects were stronger in males than females.

50 **Conclusion:** Individuals with chronic respiratory diseases, such as wheezing, COPD, and
51 asthma, have accelerated epigenetic aging in whole blood. Among COPD patients, those
52 with emphysema might exhibit higher epigenetic age acceleration. These results suggest
53 that different epigenetic clocks may capture aging mechanisms with sex-specific effects
54 on chronic respiratory diseases.

55 **Keywords:** Aging, DNA methylation, Epigenetic clock, National Health and Nutrition
56 Examination Survey, Respiratory health.

57 Chronic respiratory diseases affect over 212 million people worldwide and rank as
58 the third leading cause of mortality (1). Increasing evidence indicates that aging
59 significantly contributes to their pathogenesis linked to epigenetic changes over the
60 lifespan (2,3). DNA methylation markers, which capture gene-environment factors, may
61 underly the development of respiratory diseases and can predict biological aging rates
62 (2,3). Recent findings linked accelerated epigenetic aging with poor respiratory health
63 outcomes (2,4–7), suggesting that investigating the influence of aging on chronic
64 respiratory diseases may lead to the discovery of new therapeutic strategies and help
65 target therapies (2).

66 This study aimed to analyze public data from the National Health and Nutrition
67 Examination Surveys (NHANES) to investigate the overall association and sex-specific
68 associations of epigenetic age acceleration in whole blood with chronic respiratory
69 diseases among the U.S. adult civilian non-institutionalized population.

70 DNA methylation was measured in whole blood from adults aged ≥ 50 years from the
71 1999-2000 and 2001-2002 NHANES cycles using the Infinium MethylationEPIC array
72 (Illumina). Methylation-derived blood cell counts and epigenetic clocks were estimated,
73 including chronological age clocks (HorvathAge, HannumAge, and SkinBloodAge),
74 lifespan and health span clocks (PhenoAge, GrimAgeMort, and GrimAge2Mort), pace of
75 aging (DunedinPoAm), and DNA methylation telomere length (HorvathTelo). The
76 NHANES website details sample eligibility, laboratory procedures, and bioinformatic
77 analyses (8). Demographic and respiratory health data were recorded through
78 standardized questionnaires. Informed consent was provided by all participants, and
79 ethics review boards approved study protocols.

80 After excluding individuals top coded as aged ≥ 85 years and participants with sex
81 mismatch, we analyzed 2,402 participants in this study. Participants had an average age
82 of 65.1 ± 9.3 years, and 48.8% were females. Participants self-identified as Non-Hispanic
83 White (39.3%), Mexican American (29.0%), Black (21.8%), other Hispanic (6.4%), or
84 other/multi-racial race (3.5%). Among them, 323 (13.8%) reported wheezing in the past
85 year, 196 (8.4%) had chronic obstructive respiratory disease (COPD) (147 with chronic
86 bronchitis and 68 with emphysema), and 248 (10.6%) had asthma (94 reported current
87 asthma and 66 experienced asthma exacerbations in the past year, based on the report
88 of asthma attacks and emergency room visits).

89 We examined the association between epigenetic age and respiratory traits using
90 linear regression models adjusted for age, age², gender, race-ethnicity, and survey cycles.
91 Participants without reporting any chronic respiratory trait were included as controls.
92 Models accounted for survey weights to correct for selection, non-response, and coverage
93 biases following the NHANES analytic guidelines (8). Multiple comparisons were adjusted
94 using a false discovery rate (FDR) $<5\%$. We conducted sensitivity analyses further
95 adjusting for blood cell counts (CD8⁺ T cells, CD4⁺ T cells, NK cells, B cells, monocytes,
96 and neutrophils), and for potential clinical and socioeconomic status (SES) confounders,
97 such as smoking (never, former, and current), body mass index, education level, income,
98 occupation, and poverty-to-income ratio.

99 We observed that individuals reporting wheezing in the past year had accelerated
100 epigenetic aging compared to non-wheezing individuals (**Figure 1, Table 1**). Wheezing
101 individuals were 3.1 years higher in GrimAge2 (95% Confidence Interval [CI], 2.1, 4.1)
102 and 2.7 years higher in GrimAge (95% CI: 1.8, 3.6). Individuals with wheezing also

103 exhibited shorter average telomere length of -77.6 bp (95% CI: -118.0, -37.3). Although
104 we observed a higher 4.2% (95% CI: 2.2, 6.2) in their pace of biological aging, this finding
105 might be driven by potential clinical and SES confounders ($p>0.05$). Among wheezing
106 subjects, we observed a suggestive yet nonsignificant average 3.5% higher (95% CI: 0.2-
107 6.8, $p=0.05$, FDR=0.18) aging pace among those who had ≥ 12 wheezing attacks in the
108 past year compared to those with fewer episodes.

109 Moreover, we observed that adults with COPD had a mean epigenetic age of 2.0
110 (95% CI: 1.2, 2.8; GrimAge) and 2.0 years (95% CI: 1.2, 2.9; GrimAge2) greater than
111 those without COPD, and an increase of 3.4% (95% CI: 1.3, 5.6) in the pace of aging
112 (**Figure 1**). Nonetheless, these associations did not remain significant after adjusting for
113 smoking, BMI, and SES (**Table 1**), suggesting that accelerated epigenetic aging in COPD
114 could be driven by these exposures. Notably, smoking is a primary risk factor for COPD,
115 significantly affecting DNA methylation and mortality risk (9). Among COPD patients, those
116 with early onset (before age 40) suggestively showed 2.3 years higher (95% CI: 0.5, 4.1)
117 Hannum Age than those with late onset. Our findings reinforced previous evidence linking
118 accelerated epigenetic aging with COPD (2,4,10), in addition to identifying early onset as
119 a potential risk factor.

120 Among COPD subtypes, emphysema was associated with a mean accelerated
121 mortality-related aging of 4.4 (95% CI: 3.1, 5.8; GrimAge2) and 4.2 years (95% CI: 2.8,
122 5.6; GrimAge), along with a 7.3% (95% CI: 4.5, 10.1) increase in their pace of biological
123 aging and an average telomere reduction of -100 bp (95% CI: -163.5, -38.2) (**Figure 1**).
124 Notably, these associations remained robust after further adjustment in sensitivity
125 analyses except for telomere length reduction (**Table 1**). Conversely, only a suggestive

126 yet no significant accelerated epigenetic aging was observed in individuals with chronic
127 bronchitis (1.2 years GrimAge, 95% CI: 0.3, 2.0). Our results suggest that accelerated
128 epigenetic aging may be COPD-subtype-sensitive and pronounced in emphysema
129 individuals.

130 Regarding asthma, we observed a suggestive epigenetic age acceleration in
131 participants who ever had asthma (0.7 years GrimAge, 95% CI: 0.1, 1.3; 0.8 years
132 GrimAge2, 95% CI: 0.1, 1.6), supporting previous results observed in children with asthma
133 (5,7).

134 Finally, sex-stratified analyses revealed that the accelerated pace of biological aging
135 in COPD and the telomere length reduction associated with wheezing were stronger in
136 males than females (**Table 1**). These results suggest that different epigenetic clocks may
137 capture aging mechanisms with sex-specific effects on chronic respiratory diseases.
138 Notably, epigenetic aging has been associated with drug response in asthma in a sex-
139 specific manner (6).

140 Our study offers insights into accelerated epigenetic aging among adults with chronic
141 respiratory disorders such as wheezing, COPD (especially those with emphysema and
142 early-onset disease), and asthma, analyzing a large representative sample of the U.S.
143 adult population with high-quality data. We employed rigorous statistical methods to
144 address survey-design biases, confounders, multiple comparisons, and sex-specific
145 effects. However, several limitations must be acknowledged. The NHANES cross-
146 sectional design restricts our ability to determine the direction of causation between our
147 exposure and outcome. Although NHANES is a valuable source of health data from the
148 U.S., reliance on self-reported data may bias phenotype definition. Examining further traits

149 (e.g., lung function and inflammatory biomarkers) and evaluating pediatric populations
150 could improve our understanding of epigenetic clocks as potential biomarkers for
151 respiratory diseases across the lifespan.

152 **ACKNOWLEDGMENTS**

153 The authors thank all the participants in the NHANES 1999-2000 and 2001-2002
154 cycles, as well as all researchers and people involved in the study design, data collection,
155 data curation, sample processing, methylation data generation, and open data publication.

156 **FUNDING**

157 This work was supported by grants from the National Institute of Environmental
158 Health Sciences (NIEHS) (R01ES031259 and P42ES004705) and the National Institute
159 on Minority Health and Health Disparities (NIMHD) (R01MD011721) of the United States
160 National Institutes of Health (NIH). The study funders had no role in study design, data
161 collection, data analysis, interpretation, or report writing.

162 **COMPETING INTERESTS**

163 The authors declare they have no actual or potential competing financial interests.

164 **AUTHOR CONTRIBUTIONS**

165 JP-G and AC were involved in the conceptualization and design of the study; JP-G,
166 DK, and AC in data curation, formal analyses, and/or data interpretation; SDM and MBR
167 helped in the interpretation of results and manuscript writing; BLN and DHR generated
168 the data, supervised initial biomarker calculations, and secured funding; JP-G leads the
169 visualization and writing of the original draft; and AC was responsible for funding
170 acquisition and project supervision. All authors were involved in the critical revision of the

171 manuscript and have read and agreed to the published version of the manuscript. The
172 authors agree to be accountable for all aspects of the work, ensuring its scientific accuracy
173 and integrity.

174 **DATA AVAILABILITY**

175 Demographic data, health records, and DNA methylation epigenetic clocks
176 estimated in the analyzed participants are publicly available on the NHANES website. The
177 full summary statistic report of all association analyses supporting the main conclusions
178 of this study will be openly available in the Zenodo repository (DOI:
179 10.5281/zenodo.14549722) after the publication of the manuscript.

180 **RESEARCH IMPACT**

181 This study provides valuable information on accelerated epigenetic aging in subjects
182 with chronic respiratory diseases from the nationally representative NHANES survey in
183 the U.S. We identified for the first time accelerated epigenetic age in participants with
184 wheezing, and validated the relationship between COPD, asthma, and epigenetic age
185 acceleration. Our results support the hypothesis that epigenetic aging biomarkers might
186 help guide respiratory disease management and help target interventions.

187 **REFERENCES**

- 188 1. GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic
189 respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of
190 Disease Study 2019. *EClinicalMedicine*. 2023;59:101936.
- 191 2. Hernandez Cordero AI, Leung JM. ERJ advances: epigenetic ageing and leveraging
192 DNA methylation in chronic respiratory diseases. *Eur Respir J*. 2024;64(5):2401257.
- 193 3. Melén E, Zar HJ, Siroux V, Shaw D, Saglani S, Koppelman GH, et al. Asthma Inception:
194 Epidemiologic Risk Factors and Natural History Across the Life Course. *Am J Respir
195 Crit Care Med*. 2024;210(6):737–54.
- 196 4. Hernández Cordero AI, Yang CX, Yang J, Horvath S, Shaipanich T, Maclsaac J, et al.
197 Airway Aging and Methylation Disruptions in HIV-associated Chronic Obstructive
198 Pulmonary Disease. *Am J Respir Crit Care Med*. 2022;206(2):150–60.
- 199 5. Peng C, Cardenas A, Rifas-Shiman SL, Hivert MF, Gold DR, Platts-Mills TA, et al.
200 Epigenetic age acceleration is associated with allergy and asthma in children in Project
201 Viva. *J Allergy Clin Immunol*. 2019;143(6):2263-2270.e14.
- 202 6. Nwanaji-Enwerem JC, Osborne A, Cardenas A. Nasal Epigenetic Age and Systemic
203 Steroid Response in Pediatric Emergency Department Asthma Patients. *Allergy*.
204 2022;77(1):307–9.
- 205 7. Cardenas A, Sordillo JE, Rifas-Shiman SL, Chung W, Liang L, Coull BA, et al. The nasal
206 methylome as a biomarker of asthma and airway inflammation in children. *Nat
207 Commun*. 2019;10(1):3095.


- 208 8. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics
209 (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S.
210 Department of Health and Human Services, Centers for Disease Control and
211 Prevention. 2024 [accessed Nov 2024]. Available from:
212 <https://wwwn.cdc.gov/nchs/nhanes/Default.aspx>
- 213 9. Morrow JD, Make B, Regan E, Han M, Hersh CP, Tal-Singer R, et al. DNA Methylation
214 Is Predictive of Mortality in Current and Former Smokers. *Am J Respir Crit Care Med*.
215 2020;201(9):1099–109.
- 216 10. Breen M, Nwanaji-Enwerem JC, Karrasch S, Flexeder C, Schulz H, Waldenberger
217 M, et al. Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary
218 disease and decreased lung function in two prospective cohort studies. *Aging*.
219 2020;12(16):16539–54.
- 220

Table 1. Sensitivity and sex-stratified analyses of the statistically significant associations between epigenetic aging biomarkers and respiratory health traits.

Epigenetic clock	Sensitivity analyses				Stratified analyses by sex			
	Clinical and SES variables		Blood cell counts		Males		Females	
	Estimate (95% CI)	p-value	Estimate (95% CI)	p-value	Estimate (95% CI)	p-value	Estimate (95% CI)	p-value
Wheezing								
GrimAge2	0.77 (0.20, 1.34)	0.027	2.19 (1.54, 2.84)	1.23x10⁻⁵	2.48 (1.64, 3.32)	9.55x10⁻⁶	1.94 (0.89, 2.98)	0.002
GrimAge	0.65 (0.17, 1.14)	0.027	1.91 (1.31, 2.52)	2.15x10⁻⁵	2.11 (1.33, 2.89)	2.78x10⁻⁵	1.73 (0.77, 2.68)	0.002
DunedinPoAm	0.01 (-0.01, 0.02)	0.261	0.03 (0.02, 0.04)	2.44x10⁻⁴	0.03 (0.01, 0.04)	0.001	0.03 (0.01, 0.05)	0.012
HorvathTelo	-0.03 (-0.06, -0.005)	0.046	-0.06 (-0.08, -0.03)	0.001	-0.09 (-0.13, -0.06)	9.91x10⁻⁵	-0.03 (-0.06, 0.004)	0.100
HannumAge	0.33 (-0.22, 0.87)	0.268	0.65 (0.17, 1.13)	0.019	0.48 (-0.20, 1.16)	0.180	0.79 (-0.12, 1.70)	0.104
PhenoAge	0.21 (-0.59, 1.01)	0.625	0.89 (0.12, 1.67)	0.041	1.01 (0.05, 1.97)	0.052	0.82 (-0.25, 1.89)	0.148
COPD								
GrimAge	0.53 (-0.23, 1.30)	0.206	1.62 (0.77, 2.47)	0.002	2.38 (1.1, 3.66)	0.002	1.29 (0.06, 2.52)	0.052
GrimAge2	0.51 (-0.23, 1.24)	0.209	1.63 (0.79, 2.48)	0.002	2.62 (1.27, 3.97)	0.001	1.21 (-0.06, 2.47)	0.076
HannumAge	1.10 (0.21, 1.98)	0.038	1.08 (0.44, 1.72)	0.005	0.94 (-0.52, 2.4)	0.220	1.15 (0.12, 2.17)	0.039
DunedinPoAm	0.01 (-0.01, 0.03)	0.236	0.03 (0.01, 0.05)	0.007	0.05 (0.01, 0.08)	0.014	0.02 (-0.01, 0.05)	0.135
HorvathTelo	-0.01 (-0.05, 0.03)	0.569	-0.03 (-0.06, 0.003)	0.098	-0.06 (-0.14, 0.01)	0.100	-0.02 (-0.07, 0.02)	0.264
COPD age onset (early than 40 years)								
HannumAge	2.89 (0.64, 5.15)	0.045	2.32 (0.89, 3.74)	0.008	0.68 (-1.39, 2.75)	0.535	2.72 (0.68, 4.76)	0.019
Emphysema								
GrimAge2	1.21 (0.37, 2.06)	0.020	2.41 (1.44, 3.37)	2.37x10⁻⁴	2.98 (1.85, 4.10)	3.85x10⁻⁵	2.78 (1.51, 4.06)	3.36x10⁻⁴
GrimAge	1.19 (0.26, 2.11)	0.033	2.37 (1.40, 3.35)	2.97x10⁻⁴	2.56 (1.44, 3.67)	1.98x10⁻⁴	2.84 (1.55, 4.12)	2.98x10⁻⁴
DunedinPoAm	0.02 (0.004, 0.04)	0.040	0.04 (0.02, 0.06)	0.001	0.06 (0.03, 0.08)	2.87x10⁻⁴	0.05 (0.02, 0.07)	0.001
HorvathTelo	-0.02 (-0.07, 0.03)	0.397	-0.05 (-0.09, -0.01)	0.020	-0.08 (-0.14, -0.02)	0.012	-0.05 (-0.10, -0.01)	0.034

Only nominal associations between epigenetic clocks and respiratory traits in the main model ($p < 0.05$) are represented in this table. Main models were adjusted for age, age², gender, race-ethnicity, and survey cycle, and corrected by survey weights. Sensitivity analyses included main covariates in addition to the specific confounders. Clinical and socioeconomic status confounders included body mass index, smoking, education level, occupation, income, and poverty-to-income ratio. Blood cell counts were estimated from DNA methylation data. Significant p -values are highlighted in boldface. **Abbreviations:** 95% CI: 95% confidence interval, COPD: chronic obstructive pulmonary disease, SES: socioeconomic status.

223 **FIGURES**



224

225 **Figure 1.** Forest plot displaying the estimates and 95% confidence intervals of the associations between epigenetic aging biomarkers
 226 and chronic respiratory diseases. Only nominal associations ($p < 0.05$) are represented, and those significant after multiple comparison
 227 adjustments using a false discovery rate (FDR) $< 5\%$ are marked with an asterisk. Positive estimates indicate accelerated epigenetic
 228 aging, except for HorvathTelo, since shorter telomere lengths indicate accelerated aging. The vertical dashed line at zero represents
 229 no association. Abbreviations. 95% CI: 95% confidence interval, COPD: chronic respiratory disease.

